FDA Greenlights PTC's Groundbreaking Brain-Delivered Gene Therapy
TL;DR Summary
The FDA has approved Kebilidi, the first gene therapy for treating aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder affecting neurotransmitter production. Administered via brain infusions, Kebilidi has shown efficacy in improving motor function in patients with severe AADC deficiency. The approval was granted under the Accelerated Approval pathway, with ongoing trials to confirm its clinical benefits. The therapy is developed by PTC Therapeutics, Inc., and uses the SmartFlow Neuro Cannula for administration.
- FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency FDA.gov
- PTC wins FDA approval for first brain-delivered gene therapy Kebilidi FiercePharma
- US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder Reuters
- FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe Endpoints News
- ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain AccessWire
Reading Insights
Total Reads
0
Unique Readers
13
Time Saved
3 min
vs 4 min read
Condensed
90%
739 → 75 words
Want the full story? Read the original article
Read on FDA.gov